CD4-Positive T-Lymphocytes
"CD4-Positive T-Lymphocytes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.
Descriptor ID |
D015496
|
MeSH Number(s) |
A11.118.637.555.567.569.200 A15.145.229.637.555.567.569.200 A15.382.490.555.567.569.200
|
Concept/Terms |
CD4-Positive T-Lymphocytes- CD4-Positive T-Lymphocytes
- CD4 Positive T Lymphocytes
- CD4-Positive T-Lymphocyte
- T-Lymphocyte, CD4-Positive
- T-Lymphocytes, CD4-Positive
- CD4-Positive Lymphocytes
- CD4-Positive Lymphocyte
- Lymphocyte, CD4-Positive
- Lymphocytes, CD4-Positive
- T4 Cells
- T4 Cell
- T4 Lymphocytes
- T4 Lymphocyte
|
Below are MeSH descriptors whose meaning is more general than "CD4-Positive T-Lymphocytes".
Below are MeSH descriptors whose meaning is more specific than "CD4-Positive T-Lymphocytes".
This graph shows the total number of publications written about "CD4-Positive T-Lymphocytes" by people in this website by year, and whether "CD4-Positive T-Lymphocytes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1993 | 0 | 4 | 4 |
1994 | 4 | 6 | 10 |
1995 | 5 | 8 | 13 |
1996 | 4 | 3 | 7 |
1997 | 3 | 4 | 7 |
1998 | 1 | 6 | 7 |
1999 | 3 | 4 | 7 |
2000 | 1 | 7 | 8 |
2001 | 3 | 5 | 8 |
2002 | 8 | 8 | 16 |
2003 | 12 | 11 | 23 |
2004 | 9 | 12 | 21 |
2005 | 17 | 11 | 28 |
2006 | 14 | 11 | 25 |
2007 | 14 | 15 | 29 |
2008 | 18 | 14 | 32 |
2009 | 18 | 15 | 33 |
2010 | 12 | 15 | 27 |
2011 | 15 | 18 | 33 |
2012 | 17 | 12 | 29 |
2013 | 17 | 10 | 27 |
2014 | 12 | 17 | 29 |
2015 | 10 | 10 | 20 |
2016 | 15 | 9 | 24 |
2017 | 14 | 12 | 26 |
2018 | 13 | 13 | 26 |
2019 | 6 | 9 | 15 |
2020 | 8 | 16 | 24 |
2021 | 3 | 12 | 15 |
2022 | 2 | 10 | 12 |
2023 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "CD4-Positive T-Lymphocytes" by people in Profiles.
-
Relationships between T-lymphocytes and physical function in adults with chronic lymphocytic leukemia: Results from the HEALTH4CLL pilot study. Eur J Haematol. 2023 Jun; 110(6):732-742.
-
Sialokinin in mosquito saliva shifts human immune responses towards intracellular pathogens. PLoS Negl Trop Dis. 2023 02; 17(2):e0011095.
-
Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy. Nat Cancer. 2023 02; 4(2):222-239.
-
Immune-related pan-cancer gene expression signatures of patient survival revealed by NanoString-based analyses. PLoS One. 2023; 18(1):e0280364.
-
The diagnosis of severe combined immunodeficiency (SCID): The Primary Immune Deficiency Treatment Consortium (PIDTC) 2022 Definitions. J Allergy Clin Immunol. 2023 02; 151(2):539-546.
-
A human STAT3 gain-of-function variant confers T cell dysregulation without predominant Treg dysfunction in mice. JCI Insight. 2022 Nov 08; 7(21).
-
MPN-238 Single-Cell RNA Profiling of Myelofibrosis Patients Reveals Pelabresib-Induced Decrease of Megakaryocytic Progenitors and Normalization of CD4+ T Cells in Peripheral Blood. Clin Lymphoma Myeloma Leuk. 2022 Oct; 22 Suppl 2:S331-S332.
-
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response. Clin Cancer Res. 2022 09 01; 28(17):3695-3708.
-
Impact of CD4+ T-cell count on sustained virologic response to direct-acting antivirals in hepatitis C virus monoinfected cancer patients: a prospective observational study. Diagn Microbiol Infect Dis. 2022 Jul; 103(3):115719.
-
BHLHE40 Regulates the T-Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy. Cancer Immunol Res. 2022 05 03; 10(5):597-611.